Myriad Genetics, Inc. (MYGN)
| Previous Close | 26.68 |
| Open | 27.05 |
| Bid | 27.39 x 1100 |
| Ask | 27.51 x 800 |
| Day's Range | 26.93 - 28.04 |
| 52 Week Range | 23.55 - 36.95 |
| Volume | |
| Avg. Volume | 572,472 |
| Market Cap | 2.175B |
| Beta (5Y Monthly) | 1.58 |
| PE Ratio (TTM) | 35.01 |
| EPS (TTM) | 0.78 |
| Earnings Date | Feb. 21, 2022 - Feb. 25, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.25 |
- GlobeNewswire
Myriad Genetics CEO Paul Diaz to Speak at 40th Annual J.P. Morgan Health Care Conference
SALT LAKE CITY, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will provide an update on the execution of the company’s strategic transformation and growth plans at the 40th Annual J.P. Morgan Health Care Conference at 2:15 p.m. ET on Jan. 11, 2022. Diaz will discuss the growing role of genetic insights in context with industry trends, new commercial capabilities and products that advance he
- GlobeNewswire
Myriad Genetics Chief Scientific Officer Jerry Lanchbury Retires after 19 Years of Service
Nationwide search for permanent successor underwaySALT LAKE CITY, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the retirement of Jerry Lanchbury Ph.D. as chief scientific officer (CSO), after more than 19 years of distinguished service. A national search for a permanent CSO is underway. Lanchbury will provide consulting and scientific advisory services for Myriad Genetics through the end of the first
- Zacks
Here's Why You Should Hold on to Myriad Genetics (MYGN) for Now
Investors are optimistic about Myriad Genetics (MYGN), given robust volume growth for GeneSight and prenatal testing.
